Frederik König

Frederik König

Auto-generated profile, based on publicly available information

Frederik König

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2022 in Immunotherapy
Verified
Journal Article
Closed access
TYTakafumi Yanagisawa
Takafumi Yanagisawa
KMKeiichiro Mori
Keiichiro Mori
SKSatoshi Katayama
Satoshi Katayama
HMHadi Mostafaei
Hadi Mostafaei
FQFahad Quhal
Fahad Quhal
SSShahrokh F. Shariat
Shahrokh F. Shariat
Aim: We aimed to assess the prognostic value of pretreatment hematological biomarkers in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). Metho... Plain language summary Identifying the predictive/prognostic factors that can be applied to daily clinical practice is mandatory to facilitate the use of immune checkpoint inhibitors. Some pretreat...

1 January 2022 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Open access
ELEkaterina Laukhtina
Ekaterina Laukhtina
RMReza Sari Motlagh
Reza Sari Motlagh
KMKeiichiro Mori
Keiichiro Mori
SKSatoshi Katayama
Satoshi Katayama
PRPawel Rajwa
Pawel Rajwa
SSShahrokh F. Shariat
Shahrokh F. Shariat
To determine the oncologic and toxicity outcomes of adjuvant immunotherapy with immune checkpoint inhibitors (ICIs) compared to adjuvant chemotherapy in patients treated with radical surgery for urothelial carcinoma (UC). We used the Bayesian approach in the network meta-analysis of different therapy regimens compared to observation or placebo. Nine studies comprised of 2,444 patients met the eligibility criteria. In bladder UC, chemotherapy, atezolizumab, and nivolumab did not improve disease progression compared to observation/placebo. In upper tract UC (UTUC), chemotherapy was significantly associated with a lower likelihood of disease progression compared to observation/placebo, while atezolizumab and nivolumab were not. Based on the analysis of the treatment ranking, adjuvant chemotherapy appeared as the best treatment approach in both bladder UC and UTUC. The risk of adverse events with ICIs was comparable to that of observation/placebo. Our analysis suggests a superior oncologic benefit to adjuvant chemotherapy over ICIs in patients treated with radical surgery for both bladder UC and UTUC.

21 July 2023 in BJU International
Verified
Journal Article
Open access
PMPhillip Marks
Phillip Marks
RDRoland Dahlem
Roland Dahlem
FJFlorian Janisch
Florian Janisch
JKJakob Klemm
Jakob Klemm
LKLennart Kühnke
Lennart Kühnke
MVMalte W. Vetterlein
Malte W. Vetterlein
Objectives: To present a surgical modification for the repair of bulbar urethral strictures containing short, highly obliterative segments and report on long‐term objective and patient‐reported outcomes. Patients and methods: We considered patients undergoing bulbar buccal mucosal graft urethroplasty (BMGU) between July 2016 and December 2019. Eligibility criteria for mucomucosal anastomotic non‐transecting augmentation (MANTA) urethroplasty were strictures of ≥2 cm with an obliterative segment of ≤1.5 cm. The stricture is approached ventrally to avoid extensive dissection and mobilisation. Dorsally, the scar is superficially excised and the spongiosum is left intact. Dorsal mucomucosal anastomosis is complemented by ventral onlay graft. Perioperative characteristics were prospectively collected including uroflowmetry data and validated patient‐reported outcome measures on voiding, erectile, and continence function. We evaluated functional follow‐up, incorporating patient‐reported (lower urinary tract symptoms [LUTS] score) and functional success. Recurrence was defined as need of re‐treatment. Results: Of 641 men treated with anterior BMGU, 54 (8.4%) underwent MANTA urethroplasty. Overall, 26 (48%) and 45 (83%) had a history of dilatation and urethrotomy, respectively, and 14 (26%) were redo cases. Location was bulbar in 38 (70%) and penobulbar in 16 patients (30%), and the mean (SD) graft length was 4.5 (1.4) cm. At a median (interquartile range) follow‐up of 41 (27–53) months, the functional success rate was 93%. Whereas the median LUTS score significantly improved from baseline to postoperatively (13 vs 3.5; P < 0.001), there was no change in erectile function (median International Index of Erectile Function – erectile function domain score 27 vs 24) or urinary continence (median International Consultation on Incontinence Questionnaire – Urinary Incontinence Short Form sum score 0 vs 0; all P ≥ 0.4). All patients were ‘satisfied’ (27%) or ‘very satisfied’ (73%) with the outcome of their operation. Conclusion: With excellent long‐term objective and patient‐reported outcomes, MANTA urethroplasty adds to the armamentarium for long bulbar strictures with a short obliterative segment.

1 July 2022 in European Urology Focus
Verified
Journal Article
Open access
KMKeiichiro Mori
Keiichiro Mori
VSVictor M. Schuettfort
Victor M. Schuettfort
SKSatoshi Katayama
Satoshi Katayama
ELEkaterina Laukhtina
Ekaterina Laukhtina
Benjamin PradereBenjamin Pradere
Benjamin Pradere
SSShahrokh F. Shariat
Shahrokh F. Shariat
Elevated preoperative plasma levels of the angiogenesis-related marker VEGF have been associated with worse oncological outcomes in various malignancies. To investigate the predictive/prognostic role of VEGF in patients with urothelial carcinoma of the bladder (UCB) treated with radical cystectomy (RC). VEGF plasma levels were measured preoperatively in 1036 patients with UCB who underwent RC. The correlation between plasma VEGF levels and pathological and survival outcomes was assessed using logistic regression and Cox regression analyses. Discrimination was assessed using the concordance index (C index). The clinical net benefit was evaluated using decision curve analysis (DCA). Patients with higher pretreatment plasma VEGF levels had poorer recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) according to log-rank tests (all p < 0.001). Higher VEGF levels were not independently associated with higher risk of lymph node metastasis, ≥pT3 disease, or non-organ-confined disease (all p > 0.05). Preoperative plasma VEGF levels were independently associated with RFS, CSS, and OS in preoperative and postoperative multivariable models. However, in all cases the C index increased by <0.02 and there was no improvement in net benefit on DCA. A limitation is that none of the patients received current elements of standard of care such as neoadjuvant chemotherapy. Elevated plasma VEGF levels were associated with features of biologically and clinically aggressive disease such as worse survival outcomes among patients with UCB treated with RC. However, VEGF appears to have relatively limited incremental additive value in clinical use. Further study of VEGF for UCB prognostication is warranted before routine use in clinical algorithms. Currently available models for predicting outcomes in bladder cancer are less than optimal. A protein called vascular endothelial growth factor (VEGF), which is a marker of the formation of blood vessels (angiogenesis), may have a role in predicting survival outcomes in bladder cancer.

1 January 2024 in Urology Research and Practice
Verified
Journal Article
Open access
HMHadi Mostafaei
Hadi Mostafaei
KMKeiichiro Mori
Keiichiro Mori
SASatoshi Atayama
Satoshi Atayama
FQFahad Quhal
Fahad Quhal
Benjamin PradereBenjamin Pradere
Benjamin Pradere
SSShahrokh F. Shariat
Shahrokh F. Shariat
This study aimed to perform a systematic review and meta-analysis of stretched, erect, and flaccid penis length as well as circumference according to geographic WHO regions. PubMed, Embase, Scopus, and Cochrane Library were searched for articles published until February 2024. Studies in which a healthcare professional evaluated the penis size were considered eligible. After assessing the risk of bias, a systematic review and meta-analyses were performed according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement, and the outcomes were grouped based on the WHO regions. A total of 33 studies comprising 36 883 patients were included. The risk of bias in the included studies was moderate/low. A comprehensive systematic review was done and meta-analyses performed for flaccid length [n = 28 201, mean (SE) 9.22 (0.24) cm], stretched length [n = 20 814, mean (SE) 12.84 (0.32) cm], erect length [n = 5669, mean (SE) 13.84 (0.94) cm], flaccid circumference [n = 30 117, mean (SE) 9.10 (0.12) cm], and erect circumference [n = 5168, mean (SE) 11.91 (0.18) cm]. The mean length of the stretched penis was largest in Americans [14.47 (0.90) cm]. The mean length of the flaccid penis was the largest in the Americas [10.98 (0.064) cm]. The mean flaccid penile circumference was largest in Americans [n = 29 714, mean (SE) 10.00 (0.04) cm]. Penis sizes vary across WHO regions, suggesting the need to adjust standards according to geography to better understand councilmen and their partners. These data provide a framework for discussing body image expectations and therapeutic strategies in this sensitive and emotional subject matter. Cite this article as: Mostafaei H, Mori K, Katayama S, et al. A systematic review and meta-analysis of penis length and circumference according to WHO regions: who has the biggest one?. Urol Res Pract. 2024;50(5):291-301.

28 September 2022 in BJU International
Verified
Journal Article
Open access
MDMarkus von Deimling
Markus von Deimling
Michael RinkMichael Rink
Michael Rink
JKJakob Klemm
Jakob Klemm
MKMara Koelker
Mara Koelker
FKFrederik König
Frederik König
MVMalte W. Vetterlein
Malte W. Vetterlein
Objectives: To validate the pentafecta criteria (PC) proposed by the PROMETRICS group for outcome reporting after radical cystectomy in an open radical cystectomy (ORC) cohort with long‐term follow‐up and to assess the discriminative ability of PC attainment for oncological endpoints. Patients and Methods: Between January 2009 and December 2017, 420 patients underwent ORC with pelvic lymph node dissection and urinary diversion for non‐metastatic bladder cancer. The PC were defined as reported by the PROMETRICS group. The primary endpoint was PC attainment, and oncological outcomes comprised further endpoints. We used uni‐ and multivariable logistic regression analysis to assess predictors of PC attainment. The discriminative ability of PC for overall mortality (OM), cancer‐specific mortality (CSM) and other‐cause mortality (OCM) was compared using Kaplan–Meier curves and cumulative incidence functions. After stratification by the number of PC attained, the association between PC attainment and the survival endpoints was tested on multivariable Cox regression and competing‐risks models. Results: A total of 108 patients (26%) fulfilled all PC, while 195 (46%), 77 (18%), 35 (8.3%) and five (1.2%) attained 4/5, 3/5, 2/5 and ≤1/5 PC, respectively. Increasing age‐adjusted Charlson comorbidity index (odds ratio [OR] 0.80, P = 0.015) and incontinent diversion (OR 0.38, P = 0.005) were independent predictors of PC non‐attainment. The median follow‐up was 73 months. PC attainment (≥4/5 vs 3/5 vs ≤2/5 PC attained) was used to stratify patients into groups at significantly different risk of death ( P < 0.001). A decreasing number of PC attained (<4/5) was associated with unfavourable survival estimates for both OM and CSM (all P ≤ 0.005) but not for OCM (all P ≥ 0.2). Conclusions: The PC proposed by the PROMETRICS group represent accurate quality indicators for oncological outcome reporting after ORC for non‐metastatic bladder cancer and have a distinct discriminative ability to predict long‐term OM and CSM.